Literature DB >> 11804280

Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique.

H E Miettinen1, N Paunu, I Rantala, H Kalimo, L Paljärvi, H Helin, H Haapasalo.   

Abstract

Using the novel tissue microarray technique, we studied immunohistochemical expression of cell cycle regulators p53, p21, pRb in 42 grade II oligodendrogliomas, 16 grade III anaplastic oligodendrogliomas, 10 primary and 4 recidive grade II oligoastrocytomas, 10 grade III oligoastrocytomas and 2 other grade II mixed gliomas. The p53 immunopositivity associated with malignant histology of the tumor (p = 0.01, Mann-Whitney test) and high pRb expression (p = 0.015). The p21 score associated strongly with histological grade (p < 0.001). The immunopositive tumors had a significantly higher rate of proliferation (p = 0.021). The p21 immunopositivity correlated positively with p53 immunopositivity: among the 33 p21 immunopositive tumors 30 (91%) were p53 immunopositive and only 3 were p53 immunonegative (p = 0.017). Patients with p21 immunonegative primary tumors had significantly better prognosis: among them 42 of the 46 (91%) survived, whereas only 18 of the 30 patients (60%) with p21 immunopositive primary tumors survived until the follow-up date (p = 0.0017). Statistical significance was reached in multivariate analysis as well (p = 0.01, exp(B) = 5.5). The pRb immunopositive tumors had higher proliferation rate than immunonegative tumors (p = 0.002). In multivariate variance analysis, comparing the effects of different regulatory proteins on cell proliferation, only the amount of pRb expression reached statistical significance (p = 0.004). In conclusion, the expression of p21 in oligodendrocytic tumors seems to be upregulated by p53 expression which rises with cell proliferation and malignancy as in attempt to halt cell cycle but seems to be overrun by other factors. The amount of p21 expression has independent prognostic significance and could be used in diagnosis to help the difficult evaluation of the malignancy potential of oligodendrogliomas and oligoastrocytomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11804280     DOI: 10.1023/a:1012961918848

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Molecular genetic evidence for subtypes of oligoastrocytomas.

Authors:  D Maintz; K Fiedler; J Koopmann; B Rollbrocker; S Nechev; D Lenartz; A P Stangl; D N Louis; J Schramm; O D Wiestler; A von Deimling
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

2.  Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme.

Authors:  D Arvanitis; A Malliri; D Antoniou; S Linardopoulos; J K Field; D A Spandidos
Journal:  In Vivo       Date:  1991 Jul-Aug       Impact factor: 2.155

Review 3.  Current concepts in neuro-oncology: the cell cycle--a review.

Authors:  P B Dirks; J T Rutka
Journal:  Neurosurgery       Date:  1997-05       Impact factor: 4.654

Review 4.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

5.  Expression of p53 in oligodendrogliomas.

Authors:  J M Kros; J J Godschalk; K K Krishnadath; C G Van Eden
Journal:  J Pathol       Date:  1993-12       Impact factor: 7.996

6.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma.

Authors:  H Moch; P Schraml; L Bubendorf; M Mirlacher; J Kononen; T Gasser; M J Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

7.  p53 immunoreactivity in oligodendrogliomas.

Authors:  J Pavelić; V Hlavka; M Poljak; N Gale; K Pavelić
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  The retinoblastoma gene is involved in malignant progression of astrocytomas.

Authors:  J W Henson; B L Schnitker; K M Correa; A von Deimling; F Fassbender; H J Xu; W F Benedict; D W Yandell; D N Louis
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

9.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

View more
  12 in total

1.  Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival.

Authors:  Sally Järvelä; Järvelä Sally; Helena Bragge; Bragge Helena; Niina Paunu; Paunu Niina; Timo Järvelä; Järvelä Timo; Leo Paljärvi; Paljärvi Leo; Hannu Kalimo; Kalimo Hannu; Pauli Helén; Helén Pauli; Vuokko Kinnula; Kinnula Vuokko; Ylermi Soini; Soini Ylermi; Hannu Haapasalo; Haapasalo Hannu
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

2.  Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.

Authors:  Keith L Ligon; Emmanuelle Huillard; Shwetal Mehta; Santosh Kesari; Hongye Liu; John A Alberta; Robert M Bachoo; Michael Kane; David N Louis; Ronald A Depinho; David J Anderson; Charles D Stiles; David H Rowitch
Journal:  Neuron       Date:  2007-02-15       Impact factor: 17.173

3.  Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors.

Authors:  Sally Järvelä; Immo Rantala; Alejandra Rodriguez; Heini Kallio; Seppo Parkkila; Vuokko L Kinnula; Ylermi Soini; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

4.  Immunohistochemical markers for prognosis of oligodendroglial neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

5.  Ethanol Mediates Cell Cycle Arrest and Apoptosis in SK-N-SH Neuroblastoma Cells.

Authors:  Maria Lee; Byoung-Joon Song; Yongil Kwon
Journal:  J Cancer Prev       Date:  2014-03

6.  Carbonic anhydrase IX in oligodendroglial brain tumors.

Authors:  Sally Järvelä; Seppo Parkkila; Helena Bragge; Marketta Kähkönen; Anna-Kaisa Parkkila; Ylermi Soini; Silvia Pastorekova; Jaromir Pastorek; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2008-01-04       Impact factor: 4.430

7.  Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1).

Authors:  Yuhui Liu; Nancy Yeh; Xin-Hua Zhu; Margaret Leversha; Carlos Cordon-Cardo; Ronald Ghossein; Bhuvanesh Singh; Eric Holland; Andrew Koff
Journal:  EMBO J       Date:  2007-10-18       Impact factor: 11.598

8.  Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.

Authors:  F S Pardo; D W Hsu; R Zeheb; J T Efird; P G Okunieff; D M Malkin
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

9.  DNA replication licensing and cell cycle kinetics of oligodendroglial tumours.

Authors:  S B Wharton; S Hibberd; K L Eward; D Crimmins; D A Jellinek; D Levy; K Stoeber; G H Williams
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

10.  Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors.

Authors:  Antonio Cerqueira; Alberto Martín; Catherine E Symonds; Junko Odajima; Pierre Dubus; Mariano Barbacid; David Santamaría
Journal:  Mol Cell Biol       Date:  2014-02-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.